Malecare, Author at malecare.org

Changes of PSA Doubling Time is Associated with Disease Progression in Men with Biochemically Relapsed Prostate Cancer Treated with Intermittent Androgen Deprivation

Researchers at the The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland studied the relationship between the change of PSA doubling time (PSADT) and disease progression during intermittent androgen deprivation (IAD) therapy for prostate cancer. They retrospectively analyzed the data from 96 men diagnosed with biochemically relapsed prostate cancer (BRPC) who [...]

By Malecare|2017-10-19T10:53:12-04:00April 17th, 2011|Advanced Prostate Cancer, Drugs & Treatments, Hormone Therapy, Uncategorized, Understanding APC|0 Comments

Pomegranate and Its Role In PSA Velocity

In 2005 there was a small clinical trial performed at UCLA evaluating pomegranate juice and its ability to control PSA for men with prostate cancer. The trial gave 8 oz. of POM Wonderful pomegranate juice each day in men with a rising PSA post treatment (recurrent advanced prostate cancer). This trial, which was funded by [...]

By Malecare|2020-02-04T10:12:43-05:00April 11th, 2011|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Diet and Supplements, General Information, How We Live, Me, Research, Uncategorized, Understanding APC|1 Comment

Status Update on the Budget and It’s Implications for Cancer Research

As of now, Congress and the Administration are at an impasse on FY 11 spending. If no deal is reached by Friday, government operations will shut down. This would impact cancer research and prevention programs in the following ways: * Patient enrollment in clinical trials would be discontinued; * No new grants would be awarded; [...]

By Malecare|2017-10-19T10:53:13-04:00April 6th, 2011|Advanced Prostate Cancer, Advocacy, Clinical Trials, Clinical Trials, Uncategorized|1 Comment

Dendreon Gets FDA Approval for Extra Work Stations at their New Jersey Factory

On March 10th (my birthday) Dendreon announced that it has obtained clearance of its new work stations from the FDA. The result of this clearance is the quadrupling the output from the New Jersey factory where it makes sipuleucel-T (Provenge). When Dendreon obtained FDA clearance in April of 2010, it had extremely limited manufacturing capabilities [...]

By Malecare|2011-04-06T12:16:49-04:00April 6th, 2011|Advanced Prostate Cancer, Drugs & Treatments, General Information, Uncategorized, Understanding APC, vaccines|0 Comments

Update On the Status of Funding for the DoD for fiscal 2011

There has been some movement in the House of Representatives pertaining to the issue of future funding for the Department of Defense Prostate Cancer Research Program (DoD). The budget debate continues to slog on. We still could see an eventual governmental shut down if the members of congress are still unable to either pass a [...]

By Malecare|2021-02-17T11:03:30-05:00April 5th, 2011|Advanced Prostate Cancer, Advocacy, DOD, Financial, Research, Uncategorized|0 Comments

Carboplatin – A 2nd line chemotherapy?

Carboplatin is a chemotherapy agent used for treatment of many types of cancer. Currently, it is approved by the Food & Drug Administration (FDA) for treating patients with ovarian and non-small cell lung cancer. However, some oncologists use carboplatin “off-label” for other cancers. Commonly, these “off-label” uses include testicular, stomach, and bladder cancers as well [...]

By Malecare|2021-02-17T11:03:29-05:00April 1st, 2011|Advanced Prostate Cancer, carboplatin, Chemo Therapy Failure, Clinical Trials, End-Of-Life, salvage therapy, Uncategorized|1 Comment

CME Advisory Committee Supports Medicare Payments for Provenge for Men Meeting the FDA Guidelines

The Centers for Medicare and Medicaid Services (CME) decided to review their policies pertaining to paying for Provenge, which costs $93,000 per man. Since the hearings which were held a number of months ago, we have not heard any feedback. Despite this, most of the regions have been paying for the treatment, however there have [...]

By Malecare|2011-03-30T23:12:20-04:00March 30th, 2011|Advanced Prostate Cancer, Drugs & Treatments, Financial, Politics of Cancer, Provenge, Uncategorized|0 Comments

New Phase 2 Trials For MDV3100 Begins & Another To Start Soon – On The Horizon

It was announced today that the first patient in the TERRAIN study received their first dose in the Phase 2 trial of the investigational drug MDV3100 . MDV3100 is a triple-acting oral androgen receptor antagonist that I have writing about as a drug “On The Horizon”. Triple-acting means that it blocks testosterone binding to the [...]

By Malecare|2017-10-19T10:53:13-04:00March 30th, 2011|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, MDV3100, On The Horizon, Uncategorized|0 Comments

We Still need Your Support To Insure The Survival of the Prostate Cancer Research Program (PCRP)

I have been writing about the dire need for us to reach out to our congressional delegates and demand they support funding for the Prostate Cancer Research Program (PCRP). If you have not yet contacted your congressional members, please do it. Don’t forget you also need to let your entire email list and address book [...]

By Malecare|2021-04-29T10:07:34-04:00March 29th, 2011|Advanced Prostate Cancer, Advocacy, DOD, Uncategorized, Understanding APC|0 Comments

Study Shows that Six Months of Neoadjuvant ADT Significantly Reduces Mortality in Locally Advanced Prostate Cancer

Researchers from the Trans-Tasman Radiation Oncology Group 96.01 trial study (TROG 96.01) concluded that six months of treatment with neoadjuvant androgen deprivation combined with radiation reduced the risk for disease-specific death by 49% in men with locally advanced prostate cancer. […]

By Malecare|2011-03-28T13:49:05-04:00March 28th, 2011|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, Radiotherapy, Research, Uncategorized, Understanding APC, United Kingdom - England, Northern Ireland, Scotland & Wales|0 Comments

Malecare

About Malecare